Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.70 |
| ▸ | MEN1 | O00255 | 5/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.70 |
| ▸ | USP2 | O75604 | 1/20 | 0.70 |
| ▸ | CDK4 | P11802 | 1/20 | 0.70 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.70 |
| ▸ | CCND1 | P24385 | 1/20 | 0.70 |
| ▸ | MAPT | P10636 | 4/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.56 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.49 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3115249 | 0.88 | ALDH1A1 (0.62) | ALDH1A1MEN1KMT2AUSP2CDK4 | |
| SCHEMBL5905934 | 0.84 | ALDH1A1 (0.78) | ALDH1A1MEN1KMT2AUSP2CDK4 | |
| SCHEMBL30157536 | 0.84 | ALDH1A1 (0.78) | ALDH1A1MEN1KMT2AUSP2CDK4 | |
| SCHEMBL12377760 | 0.83 | ALDH1A1 (0.76) | ALDH1A1MEN1KMT2AUSP2CDK4 | |
| SCHEMBL7940135 | 0.83 | ALDH1A1 (1.00) | ALDH1A1MEN1KMT2AUSP2CDK4 | |
| Hydrochloric Acid SCHEMBL32678251 | 0.82 | ALDH1A1 (0.75) | ALDH1A1MEN1KMT2AUSP2CDK4 | |
| Hydrochloric Acid SCHEMBL32678255 | 0.82 | ALDH1A1 (0.75) | ALDH1A1MEN1KMT2AUSP2CDK4 | |
| Hydrochloric Acid SCHEMBL16447616 | 0.82 | ALDH1A1 (0.75) | ALDH1A1MEN1KMT2AUSP2CDK4 | |
| SCHEMBL6216648 | 0.81 | ALDH1A1 (0.72) | ALDH1A1MEN1KMT2AUSP2CDK4 | |
| SCHEMBL155757 | 0.79 | ALDH1A1 (0.70) | ALDH1A1MEN1KMT2AUSP2CDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10758534-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2020-09-01 | — | — | US | disclosed |
| US-20190269683-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-09-05 | — | — | US | disclosed |
| WO-2018108627-A1 | USE OF SUBSTITUTED INDOLINYLMETHYL SULFONAMIDES, OR THE SALTS THEREOF FOR INCREASING THE STRESS TOLERANCE OF PLANTS | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2018-06-21 | — | — | WO | disclosed |
| WO-2011000566-A2 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF NEGATIVE-SENSE SSRNA VIRUS INFECTIONS | SAVIRA PHARMACEUTICALS GMBH (AT) | 2011-01-06 | — | — | WO | disclosed |
| CN-101029017-A | Production indapamide | HUAHAI PHARMACEUTICAL CO LTD Z (CN) | 2007-09-05 | — | — | CN | disclosed |
| EP-0767792-A4 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2002-11-20 | — | — | EP | disclosed |
| EP-0767792-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-04-16 | — | — | EP | disclosed |
| WO-1996000730-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1996-01-11 | — | — | WO | disclosed |
| US-4006239-A | Benzoic acid amides for mycobacterium infections | BAYER AKTIENGESELLSCHAFT (DT) | 1977-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190269683-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1B, SLC26A4 | ALDH1A1 3524/4885MEN1 4405/4885KMT2A 3837/4885 |
| US-10758534-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | CFTR, SCNN1B, SLC26A4 | ALDH1A1 3524/4885MEN1 4405/4885KMT2A 3837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.